Consideration of therapy for colorectal cancer with synchronous unresectable liver metastasis.
- Author:
De-xiang ZHU
1
;
Li REN
;
Jian-min XU
Author Information
1. Department of General Surgery, Zhongshan Hospital, Fudan University, Institute of General Surgery, Fudan University, Colorectal Cancer Research Center, Fudan University, Shanghai 200032, China. xujmin@aliyun.com.
- Publication Type:Journal Article
- MeSH:
Colorectal Neoplasms;
drug therapy;
pathology;
surgery;
therapy;
Humans;
Liver Neoplasms;
drug therapy;
secondary;
surgery
- From:
Chinese Journal of Gastrointestinal Surgery
2013;16(8):718-720
- CountryChina
- Language:Chinese
-
Abstract:
A variety of managements, including systemic and local chemotherapy, radiofrequency ablation and others, are used after multidisciplinary team discussion to improve the survival of patients with unresectable liver metastasis, and to enlarge the cohort of patients who can be managed with curative intent. Patients should be divided into different clinical groups according to characteristics of the patient and tumor, and then receive different treatments. For the patients who may be converted to be resectable after chemotherapy, we should choose efficient convertible chemotherapy with short courses to get the best response rate. For KRAS wild-type patients, cetuximab combined with FOLFOX/FOLFIRI, in which 5-fluorouracil is continuously infused, is recommended. In addition, resection of the primary tumor is recommended at the right time for asymptomatic patients with unresectable liver metastases. There is no consensus on the preferred treatment modality for systemic and local therapies.
